Equities Analysts Offer Predictions for PMVP FY2026 Earnings

PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) – Stock analysts at HC Wainwright dropped their FY2026 earnings per share estimates for PMV Pharmaceuticals in a research note issued on Wednesday, November 11th. HC Wainwright analyst R. Burns now anticipates that the company will post earnings per share of ($1.35) for the year, down from their previous estimate of ($1.03). HC Wainwright currently has a “Buy” rating and a $5.00 target price on the stock. The consensus estimate for PMV Pharmaceuticals’ current full-year earnings is ($1.20) per share. HC Wainwright also issued estimates for PMV Pharmaceuticals’ Q4 2026 earnings at ($0.21) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.23) EPS, Q3 2027 earnings at ($0.22) EPS, Q4 2027 earnings at ($0.16) EPS and FY2027 earnings at ($0.83) EPS.

A number of other analysts have also issued reports on the company. Weiss Ratings raised PMV Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, September 24th. Wall Street Zen lowered PMV Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Sunday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $4.33.

PMV Pharmaceuticals Stock Down 4.0%

Shares of NASDAQ:PMVP opened at $1.21 on Friday. The business has a 50 day moving average price of $1.39 and a 200 day moving average price of $1.31. PMV Pharmaceuticals has a twelve month low of $1.02 and a twelve month high of $1.91. The company has a market cap of $64.69 million, a price-to-earnings ratio of -0.79 and a beta of 1.52.

PMV Pharmaceuticals (NASDAQ:PMVP) last posted its quarterly earnings data on Tuesday, November 10th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.18).

Institutional Trading of PMV Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the stock. BML Capital Management LLC grew its position in PMV Pharmaceuticals by 37.5% in the 3rd quarter. BML Capital Management LLC now owns 7,330,000 shares of the company’s stock worth $12,241,000 after purchasing an additional 2,000,000 shares during the last quarter. Eversept Partners LP acquired a new position in shares of PMV Pharmaceuticals during the first quarter valued at about $2,912,000. BlackRock Inc. acquired a new position in shares of PMV Pharmaceuticals during the second quarter valued at about $1,233,000. Stonepine Capital Management LLC acquired a new position in shares of PMV Pharmaceuticals during the second quarter valued at about $718,355. Finally, Walleye Capital LLC bought a new stake in shares of PMV Pharmaceuticals in the second quarter valued at about $450,000. 90.20% of the stock is owned by institutional investors.

About PMV Pharmaceuticals

PMV Pharmaceuticals, Inc. is a clinical-stage precision oncology company focused on developing therapies that target cancer-causing mutations in the tumor suppressor protein p53. The company aims to discover and develop small-molecule medicines designed to restore the normal tumor-suppressing function of mutant p53 proteins. PMV’s lead product candidate is rezatapopt, also known as PC14586, an investigational oral therapy designed to selectively target the p53 Y220C mutation. This mutation occurs in a range of solid tumors, and rezatapopt is being evaluated for its potential to reactivate the altered p53 protein and inhibit cancer-cell growth.